BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li H, Jiang Y, Jiang X, Guo X, Ning H, Li Y, Liao L, Yao H, Wang X, Liu Y, Zhang Y, Chen H, Mao N. CCR7 guides migration of mesenchymal stem cell to secondary lymphoid organs: a novel approach to separate GvHD from GvL effect. Stem Cells 2014;32:1890-903. [PMID: 24496849 DOI: 10.1002/stem.1656] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Shen Z, Wang J, Huang Q, Shi Y, Wei Z, Zhang X, Qiu Y, Zhang M, Wang Y, Qin W, Huang S, Huang Y, Liu X, Xia K, Zhang X, Lin Z. Genetic modification to induce CXCR2 overexpression in mesenchymal stem cells enhances treatment benefits in radiation-induced oral mucositis. Cell Death Dis 2018;9:229. [PMID: 29445104 DOI: 10.1038/s41419-018-0310-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
2 Burnham AJ, Daley-Bauer LP, Horwitz EM. Mesenchymal stromal cells in hematopoietic cell transplantation. Blood Adv 2020;4:5877-87. [PMID: 33232479 DOI: 10.1182/bloodadvances.2020002646] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
3 Thanuja M Y, Anupama C, Ranganath SH. Bioengineered cellular and cell membrane-derived vehicles for actively targeted drug delivery: So near and yet so far. Adv Drug Deliv Rev 2018;132:57-80. [PMID: 29935987 DOI: 10.1016/j.addr.2018.06.012] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 13.5] [Reference Citation Analysis]
4 Liang JW, Li PL, Wang Q, Liao S, Hu W, Zhao ZD, Li ZL, Yin BF, Mao N, Ding L, Zhu H. Ferulic acid promotes bone defect repair after radiation by maintaining the stemness of skeletal stem cells. Stem Cells Transl Med 2021;10:1217-31. [PMID: 33750031 DOI: 10.1002/sctm.20-0536] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Yang SN, Pu X, Xiang SL, Chen JP, Pei L. [Brain derived neurotrophic factor enhances the role of mesenchymal stem cells in inhibiting follicular helper T cells]. Zhonghua Xue Ye Xue Za Zhi 2018;39:37-40. [PMID: 29551031 DOI: 10.3760/cma.j.issn.0253-2727.2018.01.008] [Reference Citation Analysis]
6 McGuirk JP, Smith JR, Divine CL, Zuniga M, Weiss ML. Wharton's Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease. Pharmaceuticals (Basel) 2015;8:196-220. [PMID: 25894816 DOI: 10.3390/ph8020196] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
7 Chang YJ, Zhao XY, Huang XJ. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Front Immunol 2018;9:3041. [PMID: 30619371 DOI: 10.3389/fimmu.2018.03041] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
8 Soder RP, Dawn B, Weiss ML, Dunavin N, Weir S, Mitchell J, Li M, Shune L, Singh AK, Ganguly S, Morrison M, Abdelhakim H, Godwin AK, Abhyankar S, McGuirk J. A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease. Stem Cell Rev Rep 2020;16:979-91. [PMID: 32740891 DOI: 10.1007/s12015-020-10015-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Lee S, Kim HS, Roh KH, Lee BC, Shin TH, Yoo JM, Kim YL, Yu KR, Kang KS, Seo KW. DNA methyltransferase inhibition accelerates the immunomodulation and migration of human mesenchymal stem cells. Sci Rep 2015;5:8020. [PMID: 25620445 DOI: 10.1038/srep08020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
10 Li H, Liu Q, Gao X, Zhang D, Mao S, Jia Y. IFN-γ gene loaded human umbilical mesenchymal stromal cells targeting therapy for Graft-versus-host disease. Int J Pharm 2021;592:120058. [PMID: 33220383 DOI: 10.1016/j.ijpharm.2020.120058] [Reference Citation Analysis]
11 Li H, Jiang YM, Sun YF, Li P, Dang RJ, Ning HM, Li YH, Zhang YJ, Jiang XX, Guo XM, Wen N, Han Y, Mao N, Chen H, Zhang Y. CCR7 expressing mesenchymal stem cells potently inhibit graft-versus-host disease by spoiling the fourth supplemental Billingham's tenet. PLoS One 2014;9:e115720. [PMID: 25549354 DOI: 10.1371/journal.pone.0115720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Cuesta-Gomez N, Graham GJ, Campbell JDM. Chemokines and their receptors: predictors of the therapeutic potential of mesenchymal stromal cells. J Transl Med 2021;19:156. [PMID: 33865426 DOI: 10.1186/s12967-021-02822-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Park HB, Lee JE, Oh YM, Lee SJ, Eom HS, Choi K. CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy. Exp Mol Med 2017;49:e360. [PMID: 28751785 DOI: 10.1038/emm.2017.104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
14 Blanco B, Herrero-Sánchez MD, Rodríguez-Serrano C, García-Martínez ML, Blanco JF, Muntión S, García-Arranz M, Sánchez-Guijo F, Del Cañizo C. Immunomodulatory effects of bone marrow versus adipose tissue-derived mesenchymal stromal cells on NK cells: implications in the transplantation setting. Eur J Haematol 2016;97:528-37. [PMID: 27118602 DOI: 10.1111/ejh.12765] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
15 Miao S, Tang B, Liu H, Wang Z, Shi Y, Dong Y, Liu W, Qin C, Ren H. CXCR3 blockade combined with cyclosporine A alleviates acute graft-versus-host disease by inhibiting alloreactive donor T cell responses in a murine model. Mol Immunol 2018;94:82-90. [PMID: 29288898 DOI: 10.1016/j.molimm.2017.12.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
16 Ding L, Han DM, Zheng XL, Yan HM, Xue M, Liu J, Zhu L, Guo ZK, Mao N, Ning HM, Wang HX, Heng Zhu. Infusion of haploidentical hematopoietic stem cells combined with mesenchymal stem cells for treatment of severe aplastic anemia in adult patients yields curative effects. Cytotherapy 2021;:1391. [PMID: 34799271 DOI: 10.1016/j.jcyt.2021.09.014] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Lu XX, Zhao SZ. Gene-based Therapeutic Tools in the Treatment of Cornea Disease. Curr Gene Ther 2019;19:7-19. [PMID: 30543166 DOI: 10.2174/1566523219666181213120634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Casiraghi F, Todeschini M, Azzollini N, Cravedi P, Cassis P, Solini S, Fiori S, Rota C, Karachi A, Carrara C, Noris M, Perico N, Remuzzi G. Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. Transplantation 2019;103:1121-30. [PMID: 30801518 DOI: 10.1097/TP.0000000000002611] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Dang RJ, Yang YM, Zhang L, Cui DC, Hong B, Li P, Lin Q, Wang Y, Wang QY, Xiao F, Mao N, Wang C, Jiang XX, Wen N. A20 plays a critical role in the immunoregulatory function of mesenchymal stem cells. J Cell Mol Med 2016;20:1550-60. [PMID: 27028905 DOI: 10.1111/jcmm.12849] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
20 Xu R, Ni B, Wang L, Shan J, Pan L, He Y, Lv G, Lin H, Chen W, Zhang Q. CCR2-overexpressing mesenchymal stem cells targeting damaged liver enhance recovery of acute liver failure. Stem Cell Res Ther 2022;13. [DOI: 10.1186/s13287-022-02729-y] [Reference Citation Analysis]
21 Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Fu QL, Lian Q. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7:e2062. [PMID: 26794657 DOI: 10.1038/cddis.2015.327] [Cited by in Crossref: 490] [Cited by in F6Publishing: 496] [Article Influence: 81.7] [Reference Citation Analysis]
22 Amorin B, Alegretti AP, Valim V, Pezzi A, Laureano AM, da Silva MA, Wieck A, Silla L. Mesenchymal stem cell therapy and acute graft-versus-host disease: a review. Hum Cell 2014;27:137-50. [PMID: 24903975 DOI: 10.1007/s13577-014-0095-x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 9.4] [Reference Citation Analysis]
23 Wang L, Zhu CY, Ma DX, Gu ZY, Xu CC, Wang FY, Chen JG, Liu CJ, Guan LX, Gao R, Gao Z, Fang S, Zhuo DJ, Liu SF, Gao CJ. Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. Ann Hematol 2018;97:1941-50. [PMID: 29947972 DOI: 10.1007/s00277-018-3384-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
24 Luz-crawford P, Torres MJ, Noël D, Fernandez A, Toupet K, Alcayaga-miranda F, Tejedor G, Jorgensen C, Illanes SE, Figueroa FE, Djouad F, Khoury M. The immunosuppressive signature of menstrual blood mesenchymal stem cells entails opposite effects on experimental arthritis and graft versus host diseases: Immunosuppresive Signature of MenSC. Stem Cells 2016;34:456-69. [DOI: 10.1002/stem.2244] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
25 Oliveira-Bravo M, Sangiorgi BB, Schiavinato JL, Carvalho JL, Covas DT, Panepucci RA, Neves FA, Franco OL, Pereira RW, Saldanha-Araujo F. LL-37 boosts immunosuppressive function of placenta-derived mesenchymal stromal cells. Stem Cell Res Ther. 2016;7:189. [PMID: 28038684 DOI: 10.1186/s13287-016-0448-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
26 Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MB, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ, Sensebe L. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 2016;18:151-9. [PMID: 26724220 DOI: 10.1016/j.jcyt.2015.11.008] [Cited by in Crossref: 237] [Cited by in F6Publishing: 233] [Article Influence: 33.9] [Reference Citation Analysis]
27 Ding L, Han DM, Yan HM, Zhou JX, Zheng XL, Zhu L, Xue M, Liu J, Mao N, Guo ZK, Ning HM, Wang HX, Zhu H. Infusion of haploidentical HSCs combined with allogenic MSCs for the treatment of ALL patients. Bone Marrow Transplant 2022. [PMID: 35468947 DOI: 10.1038/s41409-022-01688-5] [Reference Citation Analysis]
28 Wang L, Zhang H, Guan L, Zhao S, Gu Z, Wei H, Gao Z, Wang F, Yang N, Luo L, Li Y, Wang L, Liu D, Gao C. Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models. Oncotarget 2016;7:61764-74. [PMID: 27528221 DOI: 10.18632/oncotarget.11238] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
29 Li G, Hu Y, Chen Y, Tang Z. Strategies to Improve the Migration of Mesenchymal Stromal Cells in Cell Therapy. Translational Neuroscience and Clinics 2017;3:159-75. [DOI: 10.18679/cn11-6030_r.2017.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
30 Yousefi F, Lavi Arab F, Saeidi K, Amiri H, Mahmoudi M. Various strategies to improve efficacy of stem cell transplantation in multiple sclerosis: Focus on mesenchymal stem cells and neuroprotection. J Neuroimmunol 2019;328:20-34. [PMID: 30557687 DOI: 10.1016/j.jneuroim.2018.11.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
31 Zhou T, Yuan Z, Weng J, Pei D, Du X, He C, Lai P. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol. 2021;14:24. [PMID: 33579329 DOI: 10.1186/s13045-021-01037-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
32 Auletta JJ, Eid SK, Wuttisarnwattana P, Silva I, Metheny L, Keller MD, Guardia-Wolff R, Liu C, Wang F, Bowen T, Lee Z, Solchaga LA, Ganguly S, Tyler M, Wilson DL, Cooke KR. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation. Stem Cells 2015;33:601-14. [PMID: 25336340 DOI: 10.1002/stem.1867] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
33 Ma T, Luan S, Tao R, Lu D, Guo L, Liu J, Shu J, Zhou X, Han Y, Jia Y, Li G, Zhang H, Han W, Han Y, Li H. Targeted Migration of Human Adipose-Derived Stem Cells to Secondary Lymphoid Organs Enhances Their Immunomodulatory Effect and Prolongs the Survival of Allografted Vascularized Composites. Stem Cells 2019;37:1581-94. [PMID: 31414513 DOI: 10.1002/stem.3078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
34 Nowakowski A, Walczak P, Lukomska B, and Janowski M. Genetic engineering of mesenchymal stem cells to induce their migration and survival. Stem Cells Int. 2016;1:1-9. [PMID: 27242906 DOI: 10.1155/2016/4956063] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
35 De Becker A, Van Riet I. Mesenchymal Stromal Cell Therapy in Hematology: From Laboratory to Clinic and Back Again. Stem Cells Dev. 2015;24:1713-1729. [PMID: 25923433 DOI: 10.1089/scd.2014.0564] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
36 Cornelissen AS, Maijenburg MW, Nolte MA, Voermans C. Organ-specific migration of mesenchymal stromal cells: Who, when, where and why? Immunology Letters 2015;168:159-69. [DOI: 10.1016/j.imlet.2015.06.019] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
37 Robles JD, Liu YP, Cao J, Xiang Z, Cai Y, Manio M, Tang EH, Chan GC. Immunosuppressive mechanisms of human bone marrow derived mesenchymal stromal cells in BALB/c host graft versus host disease murine models. Exp Hematol Oncol 2015;4:13. [PMID: 26000204 DOI: 10.1186/s40164-015-0007-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
38 Kol A, Foutouhi S, Walker NJ, Kong NT, Weimer BC, Borjesson DL. Gastrointestinal microbes interact with canine adipose-derived mesenchymal stem cells in vitro and enhance immunomodulatory functions. Stem Cells Dev. 2014;23:1831-1843. [PMID: 24803072 DOI: 10.1089/scd.2014.0128] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
39 Huang Y, Wang J, Cai J, Qiu Y, Zheng H, Lai X, Sui X, Wang Y, Lu Q, Zhang Y, Yuan M, Gong J, Cai W, Liu X, Shan Y, Deng Z, Shi Y, Shu Y, Zhang L, Qiu W, Peng L, Ren J, Lu Z, Xiang AP. Targeted homing of CCR2-overexpressing mesenchymal stromal cells to ischemic brain enhances post-stroke recovery partially through PRDX4-mediated blood-brain barrier preservation. Theranostics 2018;8:5929-44. [PMID: 30613272 DOI: 10.7150/thno.28029] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
40 Ma T, Luan SL, Huang H, Sun XK, Yang YM, Zhang H, Han WD, Li H, Han Y. Upregulation of CC Chemokine Receptor 7 (CCR7) Enables Migration of Xenogeneic Human Adipose-Derived Mesenchymal Stem Cells to Rat Secondary Lymphoid Organs. Med Sci Monit 2016;22:5206-17. [PMID: 28035134 DOI: 10.12659/msm.902690] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
41 Mishra VK, Shih HH, Parveen F, Lenzen D, Ito E, Chan TF, Ke LY. Identifying the Therapeutic Significance of Mesenchymal Stem Cells. Cells. 2020;9. [PMID: 32384763 DOI: 10.3390/cells9051145] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
42 Zhang X, Huang W, Chen X, Lian Y, Wang J, Cai C, Huang L, Wang T, Ren J, Xiang AP. CXCR5-Overexpressing Mesenchymal Stromal Cells Exhibit Enhanced Homing and Can Decrease Contact Hypersensitivity. Mol Ther 2017;25:1434-47. [PMID: 28454789 DOI: 10.1016/j.ymthe.2017.04.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
43 Leovsky C, Fabian C, Naaldijk Y, Jäger C, Jang HJ, Böhme J, Rudolph L, Stolzing A. Biodistribution of in vitro-derived microglia applied intranasally and intravenously to mice: effects of aging. Cytotherapy 2015;17:1617-26. [PMID: 26432561 DOI: 10.1016/j.jcyt.2015.07.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
44 Geiger S, Ozay EI, Geumann U, Hereth MK, Magnusson T, Shanthalingam S, Hirsch D, Kälin S, Günther C, Osborne BA, Tew GN, Hermann FG, Minter LM. Alpha-1 Antitrypsin-Expressing Mesenchymal Stromal Cells Confer a Long-Term Survival Benefit in a Mouse Model of Lethal GvHD. Mol Ther 2019;27:1436-51. [PMID: 31138510 DOI: 10.1016/j.ymthe.2019.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Zheng D, Bhuvan T, Payne NL, Heng TSP. Secondary Lymphoid Organs in Mesenchymal Stromal Cell Therapy: More Than Just a Filter. Front Immunol 2022;13:892443. [DOI: 10.3389/fimmu.2022.892443] [Reference Citation Analysis]
46 Ding L, Han DM, Zheng XL, Yan HM, Xue M, Liu J, Zhu L, Li S, Mao N, Guo ZK, Ning HM, Wang HX, Zhu H. A study of human leukocyte antigen-haploidentical hematopoietic stem cells transplantation combined with allogenic mesenchymal stem cell infusion for treatment of severe aplastic anemia in pediatric and adolescent patients. Stem Cells Transl Med 2021;10:291-302. [PMID: 32978903 DOI: 10.1002/sctm.20-0345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]